Skip to content

Efficacy and safety of limonene fragrance in relieving uremic pruritus Randomized controlled clinical trial

Efficacy and safety of limonene fragrance in relieving uremic pruritus Randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099185
Enrollment
Unknown
Registered
2025-03-19
Start date
2025-03-24
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uremic pruritus patients

Interventions

Limonene fragrance treatment group :Two drops of lemon essential oil were applied to a 2×2cm clean gauze, which was fixed to the chest area of the patients clothing (about 10 cm from the nose), and th
placebo control group:Normal saline solution

Sponsors

Department of Nephrology, the First Affiliated Hospital, the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age :18-70 years old; 2. Patients who meet the diagnostic criteria for uremia (serum creatinine >707µmol/L) or chronic kidney disease stage 5 or above (glomerular filtration rate <15mL/min) or maintenance hemodialysis (dialysis months more than 12 months); 3. Meet the diagnostic criteria for pruritus: any of the following conditions can be diagnosed as pruritus: (1) skin pruritus symptoms appear for more than 3 days within 2 weeks, lasting a few minutes each time, occurring more than 3 times a day; (2) Skin itching in a fixed pattern for more than half a year.

Exclusion criteria

Exclusion criteria: 1. Patients with diabetic peripheral neuropathy; 2. Skin itching caused by skin diseases or blood diseases; 3. Active infection; 4. Mental illness or other communication problems; 5. Cholestatic liver disease or acute hepatitis; 6. Malignant tumors; 7. Allergic to citrus, lemon fruits and smells; 8. History of bronchial asthma, COPD and other chronic lung diseases; 9. Patients with olfactory disorders; 10. Pregnant women and women in pregnancy; 11. Other diseases with skin damage; 12. Patients who received treatment for itching within 30 days prior to screening: treatment with antihistamines and corticosteroids (oral, IV, or topical), opioids, gabapentin, and pregabalin.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale values;

Secondary

MeasureTime frame
Modified Duo pruritus score;Beck Depression Self-Rating Scale (BDI) score;Anxiety Self-Rating Scale (SAS) score;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactMing Bai

Department of Nephrology, Xijing Hospital, The Fourth Military Medical University

mingbai1983@126.com+86 137 7210 4001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026